Sector Update: Health Care Stocks Narrowly Stay on Positive Ground – InvestorsObserver

Sector Update: Health Care Stocks Narrowly Stay on Positive Ground – InvestorsObserver

Health care stocks hung on for narrow gains this afternoon, with the NYSE Health Care Index rising 0.2% and the SPDR Health Care Select Sector ETF (XLV) up 0.3%.
The Nasdaq Biotechnology index, however, was climbing 3.5%.
In company news, Scholar Rock (SRRK) rose nearly 11% after the specialty drug maker said its apitegromab drug candidate produced continued improvement in non-ambulatory patients with spinal muscular atrophy after 24 months.
Seagen (SGEN) added almost 13% after a Wall Street Journal report Merck (MRK) was in talks to acquire the cancer therapy company. The companies also are discussing a potential marketing agreement in case the deal runs into regulatory difficulties, the newspaper said, citing unnamed sources. Merck shares fell 0.4%.
Among decliners, UnitedHealth Group (UNH) fell 0.9% after the health care benefits manager announced its all-cash acquisition of London-traded Emis, paying 1.24 billion British pounds ($1.52), or 1,925 pence ($2.35) per share, for the health technology firm.
Addex Therapeutics (ADXN) plunged Friday, at one point sinking nearly 61% to a record low of $1.42 a share, after the Swiss biopharmaceuticals company withdrew its financial guidance and canceled a late-stage study of its dipraglurant drug candidate to treat Parkinson’s-associated dyskinesia, blaming COVID-19 concerns and staffing shortages for negatively affecting patient recruitment.
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Stock Price data may be delayed up to 15 minutes.
Copyright © 2022. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. All Rights Reserved. Portions of this content protected by US Patent numbers 7,865,496, 7,856,390, and 7,716,116. Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. Portfolio results are unaudited and based on varying investment expiration dates. Terms of Service | Privacy Policy

source


Leave a Reply

Your email address will not be published.